Silvia Yelmo-Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Silvia Yelmo-Cruz has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Armando Luis Morera-Fumero
Universidad de la Laguna, San Cristobal de La Laguna, Spain, Spain
3 shared publications - Estefania Diaz-Mesa
Department of Internal Medicine, Dermatology, and Psychiatry, University of La Laguna (ULL), 38320 Santa Cruz de Tenerife, Canary Islands, Spain
2 shared publications - María Lourdes Fernandez-Lopez
Department of Internal Medicine, Dermatology, and Psychiatry, University of La Laguna (ULL), 38320 Santa Cruz de Tenerife, Canary Islands, Spain
2 shared publications - Pedro Abreu-González
Unit of Physiology, Department of Basic Medical Sciences, University of La Laguna, 38200 Tenerife, Spain
2 shared publications A. Crisostomo-Siverio
Psychiatry, Hospital Universitario de Canarias, La Laguna, Spain
1 shared publicationAlicia Aparicio-Dominguez
Department of Psychiatry, Hospital Universitario de Canarias, La Laguna (Santa Cruz de Tenerife), Spain [ protected
1 shared publication
Latest Publications
- Open Access
- 2 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1438
Serum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study
Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.
- 2 October 2026
- Published by MDPI AG in Biomolecules
- Vol. 16 (10) , 1438
Open AccessSerum Melatonin at Admission and Discharge in Schizophrenia: A Prospective Longitudinal Controlled Study
Schizophrenia is associated with circadian and neuroendocrine disturbances, but whether circulating melatonin changes with acute clinical state remains uncertain. This prospective longitudinal controlled study measured serum melatonin at 12:00 and 00:00 in 43 hospitalized patients after admission and before discharge, and during one session in 42 healthy controls. Psychopathology was assessed using the Positive and Negative Syndrome Scale (PANSS). Nonparametric comparisons used family-specific Holm adjustment; exploratory correlations used false-discovery-rate control. In comparisons without covariate adjustment, midday concentrations were higher in patients at admission and discharge (Holm p = 0.013 and 0.007), but the differences did not remain significant after Holm correction in exploratory models adjusted for BMI, age, and sex (29 patients and 40 controls). Median within-patient changes were −0.14 pg/mL at 12:00 (95% CI −0.27 to 0.74) and 0.00 pg./mL at 00:00 (95% CI −2.00 to 6.35); both Holm p = 1.000. Total PANSS decreased by a median of 14 points among 24 complete pairs. No change-PANSS correlation survived multiplicity correction. Two daily samples demonstrate a midday–midnight concentration difference but cannot characterize circadian phase, amplitude, or total secretion. No short-term melatonin change was detected during hospitalization; this does not establish equivalence or confirm or exclude trait-biomarker status. State-marker utility remains uncertain, and patient–control differences may reflect medication, smoking, or confounding by assay plate.
- Open Access
- 6 August 2026
- Published by MDPI AG in Preprints.org
Longitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study
Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.
- 6 August 2026
- Published by MDPI AG in Preprints.org
Open AccessLongitudinal Changes in Serum Interleukin-33 Levels During Acute Psychotic Relapse and Recovery in Schizophrenia: An Admission-Discharge Study
Immune-inflammatory dysregulation plays a central role in the pathophysiology of schizophrenia (SCZ). Interleukin-33 (IL-33), a pleiotropic alarmin cytokine of the IL-1 family, modulates neuroimmune communication, glial activation, and tissue repair, yet its involvement in psychotic disorders remains poorly characterized. This study examined serum IL-33 concentrations in 21 patients experiencing an acute psychotic relapse and 21 age- and sex-matched healthy controls (HC). Using a longitudinal design, we measured serum IL-33 by ELISA at 12:00 h and 24:00 h on the day after admission and the day before discharge in patients, alongside comprehensive clinical assessment with the Positive and Negative Syndrome Scale (PANSS). Patients with SCZ exhibited significantly lower IL-33 levels than HC at all time points (p < 0.05). Notably, IL-33 concentrations increased significantly at midnight from admission to discharge (p = 0.028), paralleling clinical improvement in PANSS positive and general psychopathology scores. A robust inverse correlation between age and IL-33 levels was observed in both patients and controls (p < 0.05), independent of sex, smoking status, sampling time, and antipsychotic dosage. These findings provide the first longitudinal evidence that IL-33 is reduced during acute psychotic episodes and rises in association with clinical recovery, supporting its role as a state-dependent biomarker. Our results highlight the involvement of alarmin signalling in the neuroimmune dysregulation underlying psychotic relapse and underscore the importance of age as a critical covariate in immunopsychiatric research.
- Open Access
- 31 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81515
Corticosteroid-Induced Psychosis: A Report of Two Cases and Review of the Literature
Glucocorticoids, prescribed for their anti-inflammatory and immunosuppressive effects, are linked to psychiatric side effects, including corticosteroid-induced psychosis. This condition may manifest as affective, organic, or cognitive disturbances, and although the exact pathophysiology is not fully understood, it is believed that corticosteroids impact the hippocampus and hypothalamic-pituitary-adrenal axis, causing neuropsychiatric changes. This report presents two cases of psychosis following corticosteroid use: a 59-year-old man with rheumatoid arthritis and a 62-year-old woman with asthmatic bronchitis. Both cases demonstrated rapid symptom improvement with antipsychotic treatment, emphasizing the need for early intervention. Despite the unclear pathophysiology, corticosteroid-induced psychosis generally has a positive prognosis when promptly managed with drug discontinuation and pharmacological treatment.
- 31 March 2025
- Published by Springer Nature in Cureus
- Vol. 17 (3) , e81515
Open AccessCorticosteroid-Induced Psychosis: A Report of Two Cases and Review of the Literature
Glucocorticoids, prescribed for their anti-inflammatory and immunosuppressive effects, are linked to psychiatric side effects, including corticosteroid-induced psychosis. This condition may manifest as affective, organic, or cognitive disturbances, and although the exact pathophysiology is not fully understood, it is believed that corticosteroids impact the hippocampus and hypothalamic-pituitary-adrenal axis, causing neuropsychiatric changes. This report presents two cases of psychosis following corticosteroid use: a 59-year-old man with rheumatoid arthritis and a 62-year-old woman with asthmatic bronchitis. Both cases demonstrated rapid symptom improvement with antipsychotic treatment, emphasizing the need for early intervention. Despite the unclear pathophysiology, corticosteroid-induced psychosis generally has a positive prognosis when promptly managed with drug discontinuation and pharmacological treatment.
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (6) , 583-584
α-PVP Associated Psychosis
- 1 November 2024
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 44 (6) , 583-584
α-PVP Associated Psychosis
- Open Access
- 1 May 2023
- Vol. 51 (3) , 130-140
BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND FIRST-EPISODE PSYCHOSIS. A LONGITUDINAL ONE-YEAR PROGNOSIS STUDY
Introduction. The brain-derived neurotrophic factor (BDNF) is a neurotrophin that has been linked to the schizophrenia neurodevelopmental hypothesis. Several studies confirm that the BDNF levels in first-episode psychosis (FEP) are lower than in healthy controls (HC). However, data about evolution of BDNF levels after a FEP and about the prognostic value of these levels are controversial. Method. Serum BDNF levels at admission of 28 inpatients with FEP were compared with 28 HC. BDNF was also measured at discharge, three, six, nine and twelve months. BDNF levels are presented in ng/ml. We looked for correlation of BDNF levels with the psychotic symptomatology measured with the Positive and Negative Syndrome Scale (PANSS) and also the prognostic value of basal levels was evaluated to predict poor functionality (measured by the Global Assessment of Functioning) and/or relapse, as well as the subsequent diagnosis of a chronic psychotic disorder. Results. At admission, patients BDNF levels were significantly lower than HC levels (18.52 +/- 4.51 vs. 26.55 +/- 3.22, p<0.001). At discharge FEP levels increase until HC levels (25.95 +/- 3.96 vs. 26.55 +/- 3.22, p=0,539). Upon the following determinations, BDNF FEP levels decreased, reaching the admission values, and being significantly lower than the HC and the levels at discharge (patients: three months: 19.68 +/- 3.88; six months: 19.02 +/- 4.13; nine months: 17.64 +/- 5.24; twelve months: 17.51 +/- 3.45 vs. HC: 26.55 +/- 3.22, all p<0.001). A negative correlation was found between admission BDNF levels and the PANSS negative symptoms subscale score with a trend towards significance (r=-0.303, p=0.093). BDNF levels at admission of patients with por functionality and/or relapse at 12 months were lower than BDNF levels of patients with goof functionality and without relapse, this difference had a trend towards significance. (15.38 +/- 4.72 vs. 19.57 +/- 4.06; p=0.071). We didn't found differences between basal BDNF levels of patients who developed a chronic psychotic disorder and patients who didn't. Conclusions. Our results reinforce the neurotrophin hypothesis. Basal levels (at diagnosis) of a FEP could predict the prognosis in terms of functionality and risk of relapse in the first year.
- 1 May 2023
- Vol. 51 (3) , 130-140
Open AccessBRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF) AND FIRST-EPISODE PSYCHOSIS. A LONGITUDINAL ONE-YEAR PROGNOSIS STUDY
Introduction. The brain-derived neurotrophic factor (BDNF) is a neurotrophin that has been linked to the schizophrenia neurodevelopmental hypothesis. Several studies confirm that the BDNF levels in first-episode psychosis (FEP) are lower than in healthy controls (HC). However, data about evolution of BDNF levels after a FEP and about the prognostic value of these levels are controversial. Method. Serum BDNF levels at admission of 28 inpatients with FEP were compared with 28 HC. BDNF was also measured at discharge, three, six, nine and twelve months. BDNF levels are presented in ng/ml. We looked for correlation of BDNF levels with the psychotic symptomatology measured with the Positive and Negative Syndrome Scale (PANSS) and also the prognostic value of basal levels was evaluated to predict poor functionality (measured by the Global Assessment of Functioning) and/or relapse, as well as the subsequent diagnosis of a chronic psychotic disorder. Results. At admission, patients BDNF levels were significantly lower than HC levels (18.52 +/- 4.51 vs. 26.55 +/- 3.22, p<0.001). At discharge FEP levels increase until HC levels (25.95 +/- 3.96 vs. 26.55 +/- 3.22, p=0,539). Upon the following determinations, BDNF FEP levels decreased, reaching the admission values, and being significantly lower than the HC and the levels at discharge (patients: three months: 19.68 +/- 3.88; six months: 19.02 +/- 4.13; nine months: 17.64 +/- 5.24; twelve months: 17.51 +/- 3.45 vs. HC: 26.55 +/- 3.22, all p<0.001). A negative correlation was found between admission BDNF levels and the PANSS negative symptoms subscale score with a trend towards significance (r=-0.303, p=0.093). BDNF levels at admission of patients with por functionality and/or relapse at 12 months were lower than BDNF levels of patients with goof functionality and without relapse, this difference had a trend towards significance. (15.38 +/- 4.72 vs. 19.57 +/- 4.06; p=0.071). We didn't found differences between basal BDNF levels of patients who developed a chronic psychotic disorder and patients who didn't. Conclusions. Our results reinforce the neurotrophin hypothesis. Basal levels (at diagnosis) of a FEP could predict the prognosis in terms of functionality and risk of relapse in the first year.
- Open Access
- 1 March 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (S1) , S769-S770
Fahr’s Disease: a case report of a patient with neuropsychiatric symptoms
Fahr’s disease (FD) is a rare disorder consisting of bilateral and symmetrical calcium deposits in basal ganglia and cerebral cortex. These lesions are associated with neurological and psychiatric symptoms such as a rigid hypokinetic syndrome, mood disorders and memory and concentration abnormalities. It can be idiopathic or secondary to endocrine disorders, infectious diseases or mitochondrial myopathies. To highlight the importance of considering organic causes when evaluating patients presenting atypical psychiatric symptoms and claim the role of neuroimaging. Case report and non-systematic review of literature: sources obtained from Pubmed database. A 69-year-old man, native of Syracuse (Italy), was admitted to the Psychiatry Unit in February 2022 presenting behavioural disturbances and irritability. In July 2021 he presented the same symptoms, being mistakenly diagnosed with Bipolar Disease type I. He has no previous psychiatric history. He started with changes in his personality, short-term memory loss, aggressiveness and disorganized behaviour at the age of 66. At admission he was talkative and hyperfamiliar, presenting delusions of grandiosity, exalted affectivity and insomnia. Neurological examination showed short-term memory problems, signs of frontal disinhibition and abnormal glabellar tap sign. Blood tests, CT brain and MRI were performed to rule out organic underlying causes. Neuro-imaging found bilateral and symmetric calcifications in globus pallidus, thalamus and corpus striatum, in favour of FD. Secondary causes (abnormalities in the PTH, vitamin disorders and infectious diseases such as HIV, brucellosis or neurosyphilis) where discarded, allowing us to conclude it was probably a primary case of FD. Valproate was started as a mood stabilizer and anticonvulsant. Genetic tests were indicated. FD should be considered as a differential diagnosis in the evaluation of psychiatric symptoms, especially when atypical and/or presented with neurological symptoms. The role of neuro-imaging is essential. None Declared
- 1 March 2023
- Published by Royal College of Psychiatrists in European Psychiatry
- Vol. 66 (S1) , S769-S770
Open AccessFahr’s Disease: a case report of a patient with neuropsychiatric symptoms
Fahr’s disease (FD) is a rare disorder consisting of bilateral and symmetrical calcium deposits in basal ganglia and cerebral cortex. These lesions are associated with neurological and psychiatric symptoms such as a rigid hypokinetic syndrome, mood disorders and memory and concentration abnormalities. It can be idiopathic or secondary to endocrine disorders, infectious diseases or mitochondrial myopathies. To highlight the importance of considering organic causes when evaluating patients presenting atypical psychiatric symptoms and claim the role of neuroimaging. Case report and non-systematic review of literature: sources obtained from Pubmed database. A 69-year-old man, native of Syracuse (Italy), was admitted to the Psychiatry Unit in February 2022 presenting behavioural disturbances and irritability. In July 2021 he presented the same symptoms, being mistakenly diagnosed with Bipolar Disease type I. He has no previous psychiatric history. He started with changes in his personality, short-term memory loss, aggressiveness and disorganized behaviour at the age of 66. At admission he was talkative and hyperfamiliar, presenting delusions of grandiosity, exalted affectivity and insomnia. Neurological examination showed short-term memory problems, signs of frontal disinhibition and abnormal glabellar tap sign. Blood tests, CT brain and MRI were performed to rule out organic underlying causes. Neuro-imaging found bilateral and symmetric calcifications in globus pallidus, thalamus and corpus striatum, in favour of FD. Secondary causes (abnormalities in the PTH, vitamin disorders and infectious diseases such as HIV, brucellosis or neurosyphilis) where discarded, allowing us to conclude it was probably a primary case of FD. Valproate was started as a mood stabilizer and anticonvulsant. Genetic tests were indicated. FD should be considered as a differential diagnosis in the evaluation of psychiatric symptoms, especially when atypical and/or presented with neurological symptoms. The role of neuro-imaging is essential. None Declared
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 35 (5) , 619-621
Antibiomania
- 1 October 2015
- Published by Wolters Kluwer Health in Journal of Clinical Psychopharmacology
- Vol. 35 (5) , 619-621
Antibiomania
- 25 February 2013
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 67 (2) , 67-75
S100B and schizophrenia
The research for peripheral biological markers of schizophrenia, although abundant, has been unfruitful. In the last 2 decades, the S100B protein has made its own room in this area of research. S100B is a calcium‐binding protein that has been proposed as a marker of astrocyte activation and brain dysfunction. Research results on S100B concentrations and schizophrenia clinical diagnosis are very consistent; patients with schizophrenia have higher S100B concentrations than healthy controls. The results regarding schizophrenia subtypes and clinical characteristics are not as conclusive. Age of patients, body mass index, illness duration and age at onset have been found to show no correlation, a positive correlation or a negative correlation with S100B levels. With respect to psychopathology, S100B data are inconclusive. Positive, negative and absence of correlation between S100B concentrations and positive and negative psychopathology have been reported. Methodological biases, such as day/night and seasonal variations, the use of anticoagulants to treat biological samples, the type of analytical technique to measure S100B and the different psychopathological scales to measure schizophrenia symptoms, are some of the factors that should be taken into account when researching into this area in order to reduce the variability of the reported results. The clinical implications of S100B changes in schizophrenia remain to be elucidated.
- 25 February 2013
- Published by Wiley in Psychiatry and Clinical Neurosciences
- Vol. 67 (2) , 67-75
S100B and schizophrenia
The research for peripheral biological markers of schizophrenia, although abundant, has been unfruitful. In the last 2 decades, the S100B protein has made its own room in this area of research. S100B is a calcium‐binding protein that has been proposed as a marker of astrocyte activation and brain dysfunction. Research results on S100B concentrations and schizophrenia clinical diagnosis are very consistent; patients with schizophrenia have higher S100B concentrations than healthy controls. The results regarding schizophrenia subtypes and clinical characteristics are not as conclusive. Age of patients, body mass index, illness duration and age at onset have been found to show no correlation, a positive correlation or a negative correlation with S100B levels. With respect to psychopathology, S100B data are inconclusive. Positive, negative and absence of correlation between S100B concentrations and positive and negative psychopathology have been reported. Methodological biases, such as day/night and seasonal variations, the use of anticoagulants to treat biological samples, the type of analytical technique to measure S100B and the different psychopathological scales to measure schizophrenia symptoms, are some of the factors that should be taken into account when researching into this area in order to reduce the variability of the reported results. The clinical implications of S100B changes in schizophrenia remain to be elucidated.